Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Alnylam Pharmaceuticals, Inc.”

376 pharma patents match "Alnylam Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 376
Index total 30,257
Page 4 / 16

Quick answer

This filtered view shows 376 pharmaceutical patents matching "Alnylam Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

376 results for “Alnylam Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 11306315

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted

  2. US 11306314

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted

  3. US 11286482

    Endosomal cleavable linkers

    Alnylam Pharmaceuticals, Inc. · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted

  4. US 11286486

    Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

    Alnylam Pharmaceuticals, Inc. · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted

  5. US 11261447

    Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

    Alnylam Pharmaceuticals, Inc. · Granted Mar 1, 2022 · Expires Feb 24, 2042

    granted

  6. US 11246933

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Feb 15, 2022 · Expires Feb 10, 2042

    granted

  7. US 11229663

    Serum amyloid P component (APCS) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  8. US 11207342

    High density lipoprotein binding protein (Hdlbp/Vigilin) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted

  9. US 11198872

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted

  10. US 11198876

    Compositions and methods for inhibiting expression of TMPRSS6 gene

    Alnylam Pharmaceuticals, Inc. · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted

  11. US 11186842

    Complement component iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted

  12. US 11162098

    Complement component C5 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Nov 2, 2021 · Expires Oct 28, 2041

    granted

  13. US 11149273

    Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene

    Alnylam Pharmaceuticals, Inc. · Granted Oct 19, 2021 · Expires Oct 14, 2041

    granted

  14. US 11149276

    Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Oct 19, 2021 · Expires Oct 14, 2041

    granted

  15. US 11142766

    Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Oct 12, 2021 · Expires Oct 7, 2041

    granted

  16. US 11136582

    Ketohexokinase (KHK) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Oct 5, 2021 · Expires Sep 30, 2041

    granted

  17. US 11130953

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Sep 28, 2021 · Expires Sep 23, 2041

    granted

  18. US 11110174

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted Sep 7, 2021 · Expires Sep 2, 2041

    granted

  19. US 11079379

    Methods of treating transthyretin (TTR) mediated amyloidosis

    Alnylam Pharmaceuticals, Inc. · Granted Aug 3, 2021 · Expires Jul 29, 2041

    granted

  20. US 11071784

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Jul 27, 2021 · Expires Jul 22, 2041

    granted

  21. US 11066670

    Insulin-like growth factor binding protein, acid labile subunit (IGFALS) and insulin-like growth factor 1 (IGF-1) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jul 20, 2021 · Expires Jul 15, 2041

    granted

  22. US 11060091

    Hepatitis B virus (HBV) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted

  23. US 11053495

    Multi-targeted single entity conjugates

    Alnylam Pharmaceuticals, Inc. · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted

  24. US 11052103

    Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jul 6, 2021 · Expires Jul 1, 2041

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.